TITLE

Profiling serum biomarkers in patients with COPD: associations with clinical parameters

AUTHOR(S)
Pinto-Plata, Victor; Toso, John; Kwan Lee; Park, Daniel; Bilello, John; Mullerova, Hana; De Souza, Mary M.; Vessey, Rupert; Celli, Bartolome
PUB. DATE
July 2007
SOURCE
Thorax;Jul2007, Vol. 62 Issue 7, p595
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease associated with significant systemic consequences. Recognition of the systemic manifestations has stimulated interest in identifying circulating biomarkers in these patients. A systematic analysis was undertaken of multiple protein analytes in the serum of well characterised patients with COPD and matched controls using novel protein microarray platform (PMP) technology. Methods: Forty-eight patients (65% men) with COPD (forced expiratory volume in 1 s <55%) and 48 matched controls were studied. Anthropometric parameters, pulmonary function tests, 6-minute walk distance, the BODE index and the number of exacerbations were measured and the association of these outcomes with the baseline levels of 143 serum biomarkers measured by PMP was explored. Results: Thirty biomarker clusters were identified and ranked by computing the predictive value of each cluster for COPD (partial least squares discriminant analysis). From the 19 best predictive clusters, 2-3 biomarkers were selected based on their pathophysiological profile (chemoattractants, inflammation, tissue destruction and repair) and the statistical significance of their relationship with clinically important end points was tested. The selected panel of 24 biomarkers correlated (p<0.01) with forced expiratory volume in 1 s, carbon monoxide transfer factor, 6-minute walk distance, BODE index and exacerbation frequency. Conclusion: PMP technology can be useful in identifying potential biomarkers in patients with COPD. Panels of selected serum markers are associated with important clinical predictors of outcome in these patients.
ACCESSION #
25757869

 

Related Articles

  • Assessing inflammatory phenotypes and improving the cost-effectiveness of asthma and COPD care in the community. Thomasa, Mike; Taylor, D Robin // Primary Care Respiratory Journal;Dec2011, Vol. 20 Issue 4, p349 

    An introduction is presented in which the editors discuss the study that assesses the utility of biomarkers in the differentiation and diagnosis of asthma and chronic obstructive pulmonary disease (COPD).

  • Biomarkers improve mortality prediction in COPD.  // British Journal of Hospital Medicine (17508460);Apr2012, Vol. 73 Issue 4, p189 

    The article reports that adding white blood cell counts and measuring systemic levels changes in inflammatory markers like interleukin (IL)-6, IL-8 and C-reactive protein, improves the ability of clinical variables to predict mortality in chronic obstructive pulmonary disease (COPD) patients.

  • UK HOT-HMV TRIAL: ACCEPTABILITY AND TOLERABILITY OF HIGH PRESSURE DOMICILIARY NON-INVASIVE VENTILATION (NIV) IN COPD. Murphy, P. B.; Moxham, J.; Polkey, M. I.; Hart, N. // Thorax;Dec2011 Supplement, pA55 

    Introduction Domiciliary NIV in COPD remains controversial with previous randomised controlled trials showing little clinical benefit. However, these trials have been criticised for using low pressure NIV and consequently nocturnal hypoventilation occurs. In contrast, there are genuine concerns...

  • HRV Analysis: A Clinical and Diagnostic Tool in Chronic Obstructive Pulmonary Disease. Barbosa Bernardo, Aline Fernanda; Vanderlei, Luiz Carlos M.; Garner, David M. // ISRN Otolaryngology;2014, p1 

    This study's aim is to analyze heart rate dynamics in subjects with chronic obstructive pulmonary disease ( COPD ) by measures of heart rate variability (HRV). HRV is a simple and noninvasive measure of autonomic impulses. 38 adults were divided into two equal groups based on respiratory...

  • Authors' response. Chang, C. L.; Hancox, R. J. // Thorax;Feb2012, Vol. 67 Issue 2, p178 

    A response by C. L. Chang and R. J. Hancoxto a letter to the editor about their article "Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD" in a previous issue is presented.

  • Biomarkers Improve COPD Prognosis.  // AARC Times;Jun2012, Vol. 36 Issue 6, p68 

    The article focuses on a panel of biomarkers identified by Harvard researchers that can improve the prediction of mortality in individuals with chronic obstructive pulmonary disease (COPD).

  • Inflammatory Markers May Predict COPD Exacerbations.  // AARC Times;Sep2013, Vol. 37 Issue 9, p156 

    The article reports on the findings of a research conducted by Danish scientists showed that patients with chronic obstructive pulmonary disorder and with elevated levels of biomarkers C-reactive protein, fibrinogen, and leukocyte count may be at risk for an exacerbation.

  • Biomarkers for predicting COPD exacerbations. Pais, Ruth // Thorax;Aug2014, Vol. 69 Issue 8, p767 

    The article cites a study by researcher M. Thomsen and others published in the "Journal of the American Medical Association," which compared frequency of exacerbations in chronic obstructive pulmonary disease (COPD) patients with raised inflammatory biomarkers (IB) to patients with normal IB.

  • Novel biomarkers linked to asthma and COPD. Gibson, Peter G. // British Journal of Hospital Medicine (17508460);Apr2011, Vol. 72 Issue 4, p188 

    The article reports on an Australian study by N. M. Verills and colleagues that identified four blood-based biomarkers, predominantly liver-synthesized proteins, which may aid in the clinical diagnosis and management of asthma and chronic obstructive pulmonary disease (COPD).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics